Dry eye disease (DED) has become a public health issue recently. Since life style change, increasing and constant use of digital devices, increasing eye LASIK surgery, prevalence has increasing rapidly both in older adults and younger populations. With the increasing market in Dry eye disease, it is important to establish effective treatments. This study intends to figure out the feasibility of using Bioactive Factors in Ocular surface disease treatment, and the business model to introducing an automatic autologous bioactive factors collection device into market.